U.S. Markets closed

Stevanato Group S.p.A. (STVN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
24.32-0.36 (-1.46%)
At close: 4:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.68
Bid24.41 x 800
Ask26.00 x 1100
Day's Range24.29 - 24.67
52 Week Range16.61 - 29.18
Avg. Volume727,210
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.94
  • Business Wire

    Stevanato Group Initiates Construction on New U.S. Facility

    PIOMBINO DESE (PD), Italy, October 04, 2021--Stevanato Group (NYSE:STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that it will begin construction on its new U.S. facility in Fishers, Indiana, this month. The site, expected to be operational in 2023, is expected to enable Stevanato Group to be in closer proximity to its North America pharmaceutical customers and to provide an a

  • Reuters

    Vaccine vial maker Stevanato to fund new plants, M&A with IPO money -chairman

    Italian vaccine vials maker Stevanato Group will use funds raised from its recent listing on the New York Stock Exchange to increase production capacity and for selected acquisitions, its executive chairman told Reuters on Thursday. According to its own estimates, it provides vials to about 90% of currently marketed COVID-19 vaccine programs. The medical packaging company raised $453.5 million in its July IPO and aims to build two new plants, which will focus on its high-margin products, including a drug containment solution called EZ-Fill.

  • Business Wire

    Stevanato Group Announces Second Quarter 2021 Financial Results

    PIOMBINO DESE, Italy, August 19, 2021--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter 2021 and established full-year 2021 guidance.